10:22 AM EST - ProMIS Neurosciences, Inc. : Will give an oral presentation on its lead clinical candidate, PMN310 for Alzheimer's disease, at the annual Alzheimer's Association International Conference from July 14-18. ProMIS Neurosciences, Inc.
shares T.PMN are trading unchanged at $0.22.